{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-024618","form_type":"8-K","ticker":"SHPH","cik":"0001757499","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","filed_at":"2025-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.349089+00:00","generated_at":"2026-05-16T17:40:00.834267+00:00","sec_items":["1.01","1.02","2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Shuttle Pharma discontinues Ropidoxuridine trial, settles $557K debt for $300K","bullets":["Settlement with Theradex: $300K payment in full for ~$557K debt; both parties release claims.","Company discontinues clinical trials of Ropidoxuridine; ends enrollment and begins FDA-compliant winddown.","Additional ~$750K owed to five hospital research sites under separate agreements.","Expects majority of winddown costs in Q4 2025; amount still being assessed.","Interim CEO Christopher Cooper signs filing; trial termination follows Theradex's Oct 15 termination notice."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-024618","json":"https://secwatch.observer/filing/0001493152-25-024618.json","markdown":"https://secwatch.observer/filing/0001493152-25-024618.md","text":"https://secwatch.observer/filing/0001493152-25-024618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:40:00.834267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6f30008c7519eec9b9e1cf1efabaed03569f9830","claim":"Shuttle Pharmaceuticals Holdings, Inc. announced a restructuring affecting clinical trials of Ropidoxuridine.","evidence_excerpt":"On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001315257-26-000036","ticker":"KOP","company_name":"Koppers Holdings Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Koppers conditionally plans to shut Stickney, IL chemical operations; Q1 adjusted EPS down 19.7%","event_type":"other_material","sec_items":["2.02","2.05","5.02","5.07","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: restructuring_charge","same SEC item: 2.05, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001315257-26-000036","json":"https://secwatch.observer/filing/0001315257-26-000036.json","markdown":"https://secwatch.observer/filing/0001315257-26-000036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1315257/000131525726000036/0001315257-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1315257/000131525726000036/kop-20260507.htm"},"side_by_side_evidence":{"fact_type":"restructuring_charge","source_excerpt":"On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm","comparable_excerpt":"potentially appropriate uses for the Stickney facility following the end of production activities. The Company expects this action to result in pre-tax charges to earnings of $227 million to $262 million through the end of 2029, approximately $170 million to $195 million of which constitutes non-cash charges and approximately $57 million to $67 million of which","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1315257/000131525726000036/0001315257-26-000036-index.htm"}},{"accession":"0001477333-26-000033","ticker":"NET","company_name":"Cloudflare, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Cloudflare Q1 revenue $639.8M +34% YoY; announces 20% workforce reduction","event_type":"other_material","sec_items":["2.02","2.05","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: restructuring_charge","same SEC item: 2.05, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001477333-26-000033","json":"https://secwatch.observer/filing/0001477333-26-000033.json","markdown":"https://secwatch.observer/filing/0001477333-26-000033.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477333/000147733326000033/0001477333-26-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477333/000147733326000033/cloud-20260507.htm"},"side_by_side_evidence":{"fact_type":"restructuring_charge","source_excerpt":"On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm","comparable_excerpt":"On May 7, 2026, the Company announced a plan (the “Plan”) designed to further accelerate its evolution to an agentic AI-first operating model. As part of the Plan, the Company expects to reduce its current workforce by approximately 20%. The Company currently estimates that it will incur charges of between $140 million and $150 million in connection with the Plan","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1477333/000147733326000033/0001477333-26-000033-index.htm"}},{"accession":"0001802457-26-000021","ticker":"ORGN","company_name":"Origin Materials, Inc.","filed_at":"2026-05-01T23:59:59+00:00","headline":"Origin Materials board approves dissolution, liquidation; CEO steps down; workforce cut 59%","event_type":"other_material","sec_items":["2.05","5.02","9.01"],"materiality_score":0.95,"calibrated_materiality_score":0.95,"match_reasons":["same fact type: restructuring_charge","same SEC item: 2.05, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001802457-26-000021","json":"https://secwatch.observer/filing/0001802457-26-000021.json","markdown":"https://secwatch.observer/filing/0001802457-26-000021.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802457/000180245726000021/0001802457-26-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802457/000180245726000021/orgn-20260501.htm"},"side_by_side_evidence":{"fact_type":"restructuring_charge","source_excerpt":"On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm","comparable_excerpt":"its workforce by approximately 59%, resulting in an approximately $14.0 million decrease in annual operating expenses. Origin anticipates that it will incur approximately $2.1 million in restructuring charges in connection with the workforce reduction, primarily consisting of cash expenditures of approximately $2.1 million for severance and benefits costs.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1802457/000180245726000021/0001802457-26-000021-index.htm"}},{"accession":"0001104659-26-049837","ticker":"IAC","company_name":"IAC Inc.","filed_at":"2026-04-28T23:59:59+00:00","headline":"IAC announces name change to 'People Incorporated', restructuring with $40M cost savings, and C-suite changes","event_type":"other_material","sec_items":["2.02","7.01","2.05","5.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: restructuring_charge","same SEC item: 2.05, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-049837","json":"https://secwatch.observer/filing/0001104659-26-049837.json","markdown":"https://secwatch.observer/filing/0001104659-26-049837.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800227/000110465926049837/0001104659-26-049837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800227/000110465926049837/tm2612831d1_8k.htm"},"side_by_side_evidence":{"fact_type":"restructuring_charge","source_excerpt":"On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm","comparable_excerpt":"Ahead of its name change to \"People Incorporated\" which is expected to occur with the release of Q2 2026 earnings in August, the Company has initiated a plan to consolidate its corporate functions with those of its People Inc. business (\" People \"), through a reduction in workforce, technology integrations, and other cost-saving measures over the coming quarters (the \" Plan \"). The Plan is expected to generate annual run-rate cost savings of approximately $40 million. The Plan is expected to be completed by Q1 of 2027. The Company expects to incur approximately $14 million in severance and related expenses, $48 million in non-cash stock-based compensation expense and $0.5 million to $1 million in other costs related to the Plan.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1800227/000110465926049837/0001104659-26-049837-index.htm"}},{"accession":"0001193125-26-155861","ticker":"SNAP","company_name":"Snap Inc","filed_at":"2026-04-15T23:59:59+00:00","headline":"Snap reports Q1 rev ~$1.53B (+12% YoY), adj EBITDA ~$233M; cuts 16% of staff (~1,000 jobs)","event_type":"other_material","sec_items":["2.02","2.05","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: restructuring_charge","same SEC item: 2.05, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-155861","json":"https://secwatch.observer/filing/0001193125-26-155861.json","markdown":"https://secwatch.observer/filing/0001193125-26-155861.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1564408/000119312526155861/0001193125-26-155861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1564408/000119312526155861/d36756d8k.htm"},"side_by_side_evidence":{"fact_type":"restructuring_charge","source_excerpt":"On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm","comparable_excerpt":"increased operational efficiencies to accelerate our path toward net-income profitability. As a result, we currently estimate that we will incur pre-tax charges in the range of $95 million to $130 million, primarily consisting of severance and related costs, contract termination costs, and other impairment charges, of which $75 million to $100 million are expected","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1564408/000119312526155861/0001193125-26-155861-index.htm"}},{"accession":"0001171843-26-002302","ticker":"CRMT","company_name":"AMERICAS CARMART INC","filed_at":"2026-04-07T23:59:59+00:00","headline":"America's Car-Mart to close 42 stores (31% of total); non-cash impairment ~$14M due to capital constraints","event_type":"other_material","sec_items":["2.05","2.06","7.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: restructuring_charge","same SEC item: 2.05, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002302","json":"https://secwatch.observer/filing/0001171843-26-002302.json","markdown":"https://secwatch.observer/filing/0001171843-26-002302.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/799850/000117184326002302/0001171843-26-002302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/799850/000117184326002302/f8k_040726.htm"},"side_by_side_evidence":{"fact_type":"restructuring_charge","source_excerpt":"On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm","comparable_excerpt":"the Company expects to record a non-cash impairment charge of approximately $14 million related to assets at the closing locations.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/799850/000117184326002302/0001171843-26-002302-index.htm"}},{"accession":"0001213900-26-033878","ticker":"NDRA","company_name":"ENDRA Life Sciences Inc.","filed_at":"2026-03-25T23:59:59+00:00","headline":"ENDRA Life Sciences cuts staff, initiates strategic alternatives review; severance costs $51K","event_type":"other_material","sec_items":["2.05","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: restructuring_charge","same SEC item: 2.05, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-033878","json":"https://secwatch.observer/filing/0001213900-26-033878.json","markdown":"https://secwatch.observer/filing/0001213900-26-033878.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000121390026033878/0001213900-26-033878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000121390026033878/ea0283331-8k_endra.htm"},"side_by_side_evidence":{"fact_type":"restructuring_charge","source_excerpt":"On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm","comparable_excerpt":"on March 19, 2026, the Company reduced the number of its employees in order to reduce cash expenditures and extend its operational runway. As a result, the Company expects to incur pre-tax cash charges of approximately $51,000 associated with severance payments to former employees.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000121390026033878/0001213900-26-033878-index.htm"}},{"accession":"0001171843-26-001794","ticker":"SSM","company_name":"Sono Group N.V.","filed_at":"2026-03-19T23:59:59+00:00","headline":"Sono Group exits solar subsidiary, adopts Bitcoin treasury strategy with covered-call yield","event_type":"other_material","sec_items":["2.05","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: restructuring_charge","same SEC item: 2.05, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001794","json":"https://secwatch.observer/filing/0001171843-26-001794.json","markdown":"https://secwatch.observer/filing/0001171843-26-001794.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840416/000117184326001794/0001171843-26-001794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840416/000117184326001794/f8k_031926.htm"},"side_by_side_evidence":{"fact_type":"restructuring_charge","source_excerpt":"On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm","comparable_excerpt":"On March 14, 2026, the supervisory board of Sono Group N.V. (the “Company”) resolved to terminate all current and future funding commitments to its sole operational subsidiary, Sono Motors GmbH, and to exit the legacy solar operations conducted through Sono Motors GmbH, with immediate effect.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1840416/000117184326001794/0001171843-26-001794-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}